Dyadic International Inc. (DYAI:NASDAQ) is advancing its proprietary C1 protein expression platform at a time when the global biologics market faces increasing pressure for faster and more scalable manufacturing solutions.
The recent achievement of generating stable C1 cell lines and delivering purified recombinant protein antigens for Bundibugyo ebolavirus within roughly 15 days highlights how the technology could address urgent needs in infectious disease response.
Key Investor Takeaways
- Dyadic produced and purified two Scripps-designed antigens for Bundibugyo ebolavirus in about 15 days and delivered them for preclinical testing.
- The C1 fungal platform has shown monoclonal antibody titers above 12 g/L in seven days without requiring viral clearance steps typical of CHO systems.
- Externally funded programs with CEPI, the Gates Foundation, and FBS continue to validate C1 for both vaccine antigens and monoclonal antibodies.
- Analysts at Craig-Hallum reiterated a Buy rating with a US$5 price target in May 2026, while technical analysis points to potential near-term price objectives of US$1.30.
- The company holds a market cap of US$38.63 million with 36.44 million shares outstanding and a 52-week trading range of US$0.65 to US$1.60.
Biologics Market Opportunity and Outbreak Timing
The global biologics sector continues to expand at high-single-digit annual rates with even stronger growth projected for monoclonal antibodies. This expansion creates demand for manufacturing platforms that shorten development timelines while improving productivity and lowering costs.
Current Ebola disease activity in the Democratic Republic of the Congo and Uganda has placed additional focus on rapid antigen production. As of the CDC's May 16 update, the agency is monitoring an outbreak caused by Bundibugyo virus, a strain for which no approved vaccine or specific treatment currently exists.
Why Dyadic Stands Out
Dyadic generated stable pools of C1 cell lines and completed initial purification of two recombinant protein antigens within approximately 15 days of receiving the required plasmids, according to a July 28 release. The antigens were subsequently delivered to Fondazione Biotecnopolo di Siena and Scripps Research for preclinical evaluation as part of efforts to develop a potential non-mRNA vaccine candidate.
Chief Executive Officer Mark Emalfarb noted that the speed demonstrated could support faster, more productive, and more affordable paths for developing non-mRNA vaccines and other biologics at the scale required during active outbreaks.
Unique Advantages of the C1 Platform
C1 is Dyadic's proprietary Myceliophthora thermophila-based fungal protein-production platform, designed to develop and manufacture vaccines, monoclonal antibodies, and other recombinant proteins faster, at higher productivity, and potentially at substantially lower cost than traditional mammalian and insect-cell systems. Unlike CHO and insect-cell platforms, C1 grows rapidly, can produce greater quantities of protein in shorter manufacturing cycles, and does not require certain viral-clearance steps commonly associated with those systems. These advantages could reduce development timelines, manufacturing complexity, facility requirements, and overall production costs while increasing the number of doses that can be produced from existing biomanufacturing capacity. The platform has already demonstrated monoclonal antibody titers exceeding 12 grams per liter in just seven days, approximately half the production time of a conventional CHO antibody process. This combination of speed, yield, and manufacturing efficiency could become increasingly valuable as the global demand for biologics continues to grow. With broader validation, regulatory acceptance, and commercial adoption, C1 has the potential to help reshape biologics manufacturing by improving the economic viability of vaccines, monoclonal antibodies, and other therapeutic proteins. For Dyadic, successful adoption could create significant licensing, collaboration, and recurring revenue opportunities across multiple high-value markets. More importantly, by increasing manufacturing speed, capacity, and affordability, C1 could help expand access to potentially lifesaving biologics in regions where cost, production limitations, and supply constraints often determine whether treatments ever reach the patients who need them.
Key Catalysts and External Collaborations
Dyadic highlighted ongoing externally funded programs involving the Coalition for Epidemic Preparedness Innovations, the Gates Foundation, the European Vaccines Hub, and other organizations. A US$3.1 million Gates Foundation grant supporting monoclonal antibody programs targeting respiratory syncytial virus and malaria has been received in full.
The company also advanced a recombinant non-animal bovine chymosin enzyme toward commercialization with Denmark-based Inzymes, receiving a US$200,000 milestone payment in March 2026 for work on a product aimed at the multibillion-dollar dairy enzyme market.
Analyst Views and Technical Outlook
1A July 14 review of the stock by Technical Analyst Stewart Thomson presented a constructive view based on the company's transition to commercial-stage manufacturing and expanding partnerships. Craig-Hallum analysts reiterated a Buy rating and US$5 price target in May 2026, citing progress from early-stage development toward initial revenue generation.
Technical indicators, including MACD, RSI, and On Balance Volume, were described as supportive of potential outperformance relative to the broader biotechnology sector, with near-term objectives cited at US$1.30 and longer-term targets at US$1.90 and US$2.60.
Streetwise Ownership Overview*
Dyadic International Inc. (DYAI:NASDAQ)
| Date | Old Symbol | Old Shares | New Symbol | New Shares |
|---|---|---|---|---|
| 04/17/19 | DYAI:OTCQX | 1 | DYAI:NASDAQ | 1 |
Share Structure and Ownership
2Insiders and management hold approximately 16 percent of the company, institutions hold about 15 percent, and strategic investors hold about 9 percent, with the balance held by retail shareholders. Market capitalization stands at nearly US$38.63 million based on 36.44 million shares outstanding.
Common Questions from Investors
How quickly can the C1 platform move from plasmid receipt to purified antigen? Dyadic reported completing stable cell line generation, production, and initial purification of two Bundibugyo ebolavirus antigens in approximately 15 days.
What distinguishes C1 from traditional expression systems? C1 is a fungal platform that achieves high titers in short cycles and avoids certain viral clearance steps required in mammalian and insect cell systems, potentially lowering time and cost.
Are there approved vaccines for Bundibugyo virus? No approved vaccine or specific treatment currently targets Bundibugyo ebolavirus, the strain linked to the ongoing outbreak tracked by the CDC.
What is the current market capitalization and trading range? The company trades with a market cap near US$38.63 million within a 52-week range of US$0.65 to US$1.60.
The global Ebola vaccine market was valued at US$790.74 million in 2024 and is projected to reach US$1.4 billion by 2032 at a CAGR of 7.58 percent, according to Data Bridge Market Research. Continued validation of rapid protein production technologies could support broader adoption across vaccine and therapeutic protein markets.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Disclosure for the quote from the Stewart Thomson article published on July 14, 2026
- For the quoted article (published on July 14, 2026, Dyadic International Inc. has paid Street Smart, an affiliate of Streetwise Reports, US$4,000.
- Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.
2. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
